Measuring L-PGDS Levels in Women With Adenomyosis Compared to Control Groups
Measures L-PGDS in blood, urine and vaginal samples from women with adenomyosis.
Plain-language title generated from the registry record
Registry title: Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay
Key facts
- Where
- Nîmes, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 57 years old?
Source: NCT06864494, who can take part
Where in France
- CHU de NîmesNîmes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Trial code
- NCT06864494
- Record updated
- 18 March 2026
- Original description
Prostaglandin D2 (PGD2) has anti-inflammatory activity, particularly via Lipocalin type-prostaglandin (L-PGDS). L-PGDS has been studied in pathologies such as sleep apnea, rheumatoid arthritis, asthma and allergic phenomena, but never in adenomyosis. Adenomyosis is a estrogen-dependent multifactorial pathology whose pathophysiology is still poorly defined. This hyperestrogenism causes chronic inflammation, particularly via the activation of the prostaglandin H2 (PGH2) signaling pathway. This would lead to the excess production of prostaglandins E2 (PGE2) and F2a (PGF2a) and the decrease of PGD2 and therefore of L-PGDS, leading to the proliferation of endometrial cells in the myometrium by the epithelial-mesenchymal transition via aromatase. A preliminary study comparing the expression of L-PGDS found a significant decrease in L-PGDS in the uterus of women with adenomyosis lesions versus healthy controls. However, during this study, some information was not collected, including the patients' symptoms, preoperative radiological data and surgical indication. The study authors hypothesize that L-PGDS could be a potential tissue and circulating diagnostic marker of adenomyosis in its early stages. L-PGDS appears to be a good candidate to aid in the diagnosis of adenomyosis via a minimally invasive assay for patients (blood or urine).Read full original descriptionShow less
L-PGDS (Lipocalin Type- Prostaglandin) Quantification in Genital, Blood and Urine Samples From Adenomyosis Patients Compared to 2 Control Groups.
Prostaglandin D2 (PGD2) has anti-inflammatory activity, particularly via Lipocalin type-prostaglandin (L-PGDS). L-PGDS has been studied in pathologies such as sleep apnea, rheumatoid arthritis, asthma and allergic phenomena, but never in adenomyosis. Adenomyosis is a estrogen-dependent multifactorial pathology whose pathophysiology is still poorly defined. This hyperestrogenism causes chronic inflammation, particularly via the activation of the prostaglandin H2 (PGH2) signaling pathway. This would lead to the excess production of prostaglandins E2 (PGE2) and F2a (PGF2a) and the decrease of PGD2 and therefore of L-PGDS, leading to the proliferation of endometrial cells in the myometrium by the epithelial-mesenchymal transition via aromatase. A preliminary study comparing the expression of L-PGDS found a significant decrease in L-PGDS in the uterus of women with adenomyosis lesions versus healthy controls. However, during this study, some information was not collected, including the patients' symptoms, preoperative radiological data and surgical indication. The study authors hypothesize that L-PGDS could be a potential tissue and circulating diagnostic marker of adenomyosis in its early stages. L-PGDS appears to be a good candidate to aid in the diagnosis of adenomyosis via a minimally invasive assay for patients (blood or urine).
Inclusion: Common inclusion criteria:; The patient must have given their free and informed consent and signed the consent form; The patient must be a member or beneficiary of a health insurance plan; Adenomyosis + group:; Female; Aged 28 (≥) to 57 (≤) years; Non-menopausal; Having an indication for a total inter-ovarian hysterectomy (excluding oncology); Suffering from adenomyosis; Adenomyosis - group:; Female; Aged 28 (≥) to 57 (≤) years; Non-menopausal; Having an indication for a total inter-ovarian hysterectomy (excluding oncology); Suffering from a functional pathology other than adenomyosis; Control Group:; Female; Aged 18 (≥) to 57 (≤) years; Asymptomatic: absence of menometrorrhagia and pelvic pain; Support at the medically assisted procreation (MAP) center of the Nîmes University Hospital for male or idiopathic infertility; Indication to perform an endovaginal ultrasound as part of MAP management; Absence of uterine pathology visualized on endovaginal ultrasound.
Exclusion: Taking nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or aspirin in the 15 days prior to L-PGDS concentration measurement; History of autoinflammatory or autoimmune disease; History of atopic or asthmatic conditions; History of sleep apnea syndrome; Chronic or acute renal failure; Liver failure; History of active neoplasia or cancer; Undergoing estrogen-progestin hormonal contraception; Adenomyosis groups:; Contraindication to MRI; Control Group:; Endovaginal ultrasound refused by the patient; Presence of a functional-looking ovarian cyst on imaging (endovaginal ultrasound and/or pelvic MRI).